Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.
Lead candidate TTHX1114 is an engineered form of FGF-1 designed to stimulate proliferation and migration of corneal endothelial cells. It is initially being developed as an intracameral injection as the first pharmacologic treatment for back of the cornea surface disease (endothelial dystrophy), the leading cause of cornea transplantation surgeries.
Trefoil's second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision.
Lead candidate TTHX1114 is an engineered form of FGF-1 designed to stimulate proliferation and migration of corneal endothelial cells. It is initially being developed as an intracameral injection as the first pharmacologic treatment for back of the cornea surface disease (endothelial dystrophy), the leading cause of cornea transplantation surgeries.
Trefoil's second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision.
Location: United States, California, San Diego
Employees: 1-10
Phone: +1 858-294-0401
Total raised: $28M
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | Access Bio... | accessbio-... |
| - | Solasta Ve... | solasta-ve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.07.2019 | Series A | $28M | - |
Mentions in press and media 13
| Date | Title | Description |
| 27.11.2023 | Trefoil Therapeutics Secures $28M Series A Round | - |
| 26.11.2023 | Trefoil Therapeutics Secures $28M Series A Round | - |
| 25.11.2023 | Trefoil Therapeutics Secures $28M Series A Round | - |
| 24.11.2023 | Trefoil Therapeutics Secures $28M Series A Round | - |
| 23.11.2023 | Trefoil Therapeutics Secures $28M Series A Round | - |
| 01.12.2021 | Trefoil Therapeutics Announces Third Tranche of $28 Million Series A Financing Based on Achievement of Clinical Trial Objectives | Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have funded the third tranche of its $28 million Series A financing to support the development o... |
| 20.08.2020 | Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies | One principle guides our investments: invest in companies that will improve patients' lives. We have found that the best founders and executive teams share that belief. From our first meeting to an email this week, the Trefoil Therapeutics ... |
| 25.07.2019 | Trefoil Gets $28M Series A to Work on Vision Diseases | San Diego biotech Trefoil Therapeutics recently brought in a $28 million Series A round for work on vision diseases... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a subscriber? Sign in 52 weekly issues Su... |
| 23.07.2019 | Trefoil moves closer to a clinical trial: Announcing our follow on investment | Trefoil Therapeutics, Inc., an early-stage biopharmaceutical company and ExSight Ventures portfolio company, announced their $28 million Series A financing. Trefoil is developing a regenerative approach to treating corneal dystrophies and o... |
| 16.07.2019 | Trefoil Therapeutics Secures $28M Series A Round | - |
Show more